SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway
Anticancer Research · 2025
DOI: 10.21873/anticanres.17574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Hyun-Ha Hwang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Apoptosis, Lung Neoplasms, Receptor Protein-Tyrosine Kinases.
Abstract (Originalsprache)
BACKGROUND/AIM: SH003, a novel herbal mixture consisting of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii Maximowicz, has shown promising anti-cancer effects in various cancers, including non-small cell lung cancer (NSCLC), which comprises approximately 85% of all lung cancer cases. Characterized by high mortality rates due to late-stage diagnosis and frequent development of resistance to traditional therapies, NSCLC is a significant clinical challenge. This study investigated the anti-cancer effects of SH003 on NSCLC cells, focusing on its role in modulating receptor tyrosine kinase (RTK) signaling pathways. MATERIALS AND METHODS: NSCLC cell lines (A549, H460, HCC827) were treated with SH003 to evaluate cell viability (MTT assay), colony formation, apoptosis (Annexin V/7-AAD staining, western blot), and cell cycle distribution (PI staining). Phosphorylation of RTKs and related signaling molecules was analyzed using a phospho-RTK array and western blot. In vivo anti-tumor effects were assessed using an A549 xenograft mouse model treated orally with SH003. RESULTS: NSCLC cell lines A549, H460, and HCC827 treated with SH003 showed significant, dose-dependent cell viability and colony formation reductions. SH003 induced apoptosis, evidenced by increased cleaved PARP and caspase-8 levels, and caused G1/S cell cycle arrest. Additionally, SH003 treatment decreased phosphorylation of multiple receptor tyrosine kinases (RTKs), including ErbB4, FGFR1, FGFR3, and PDGFRβ, as confirmed by an RTK array. In an A549 xenograft mouse model, SH003 inhibited tumor growth without affecting body weight, indicating low systemic toxicity. CONCLUSION: SH003 is a promising multi-target therapeutic agent for NSCLC, offering a novel strategy to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.
- Department of Biotechnology, Korea National University of Transportation, Chungbuk, Republic of Korea.
- Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
- Institute for Research Center in Jaein R&P, Seoul, Republic of Korea.
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea; epiko@khu.ac.kr.
Zitieren
APA
Hwang, H. H., Yoo, J. S., Je, J. H., Lee, H. C., Kim, T. H., Sim, Y. B., Cho, K. J., Kim, T., Cho, S. G., & Ko, S. G. (2025). SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway. Anticancer Research. https://doi.org/10.21873/anticanres.17574
Vancouver
Hwang HH, Yoo JS, Je JH, Lee HC, Kim TH, Sim YB, et al. SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway. Anticancer Research. 2025. doi:10.21873/anticanres.17574
BibTeX
@article{Hwang2025,
author = {Hwang, Hyun-Ha and Yoo, Ji-Sung and Je, Jeong-Hui and Lee, Hyeong-Chan and Kim, Tae Hun and Sim, Yun-Beom and Cho, Kwang-Jin and Kim, Taehyoun and Cho, Sung-Gook and Ko, Seong-Gyu},
title = {SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17574}
}
EUVIMED